Probiotic Strains for Recurrent UTI: GR-1, RC-14 and Beyond

The two probiotic strains with the longest research history for recurrent urinary tract infection are Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. They have been studied for over 30 years. They appear in the only randomised trial that compared a probiotic head-to-head with antibiotic prophylaxis in postmenopausal women. And on the supplement aisle, you will struggle to find a bottle that lists either strain code.

That gap, between what has actually been tested and what is sold as a “urinary probiotic”, is the reason most people taking probiotic strains for recurrent UTI are not getting the formulations the trials studied.

Key Takeaways

• L. rhamnosus GR-1 and L. reuteri RC-14 have the most clinical history for oral UTI prevention; L. crispatus CTV-05 (Lactin-V) has the strongest data for vaginal delivery
• The Beerepoot 2012 trial in 252 postmenopausal women fell short of non-inferiority versus antibiotics, but the probiotic group avoided the antibiotic-resistance buildup seen in the comparator arm
• Stapleton’s 2011 Phase 2 trial of vaginal L. crispatus CTV-05 cut UTI recurrence from 27% to 15% over 10 weeks
• The 2024 Murina trial directly compared oral and vaginal probiotics; vaginal delivery outperformed oral, with combined therapy lowest at 31.8% UTI incidence vs 70.4% placebo
• A probiotic label without a strain code is effectively untested; species-only labelling means the organism inside has not been verified against clinical trial cultures
• Trial doses ran 1–2 billion CFU daily, taken 8 to 24 weeks before UTI rate changes appeared

The Vaginal Microbiome Is the Frontline

To understand why specific strains matter, start with where most UTIs begin.

Around 80% of uncomplicated UTIs in women are caused by E. coli migrating from the gut through the perineum, colonising the vagina, then ascending the urethra into the bladder [1]. The vagina is the staging ground. Whether bacteria get to mount that ascent depends largely on which Lactobacillus species are dominant there.

A healthy premenopausal vagina is typically dominated by one of four Lactobacillus species: L. crispatus, L. iners, L. gasseri, or L. jensenii. Of these, L. crispatus dominance is associated with the lowest UTI risk. The mechanism is not mysterious. L. crispatus produces lactic acid that drops vaginal pH below 4.5, releases hydrogen peroxide that inhibits gram-negative bacteria, and physically occupies the binding sites on epithelial cells that E. coli would otherwise use to colonise [2].

What disrupts this? Antibiotics, menopause-driven oestrogen loss, spermicide, and recurrent infection itself. Each pushes the vaginal microbiome away from Lactobacillus dominance and toward more diverse anaerobic communities. This is the same shift seen in bacterial vaginosis, and a parallel shift seen in postmenopausal recurrent UTI.

This is the biology that makes probiotic strains for recurrent UTI a coherent strategy. You are not adding generic “good bacteria” to a generic system. You are trying to restore a specific microbial community at a specific anatomical site.

GR-1 and RC-14: The Pair With the Longest Research History

Lactobacillus rhamnosus GR-1 was originally isolated from a healthy woman’s distal urethra in the 1980s by Gregor Reid and Andrew Bruce at the University of Western Ontario. L. reuteri RC-14 (originally classified as L. fermentum) came from the same research program. The pair has been the basis of probably 30 published clinical trials for urogenital health.

Three properties got them onto the candidate list:

1. They survive transit through stomach acid and bile when delivered orally
2. After oral ingestion, they appear in vaginal cultures within 1–2 weeks in roughly 60–80% of women [3]
3. In vitro, they produce biosurfactants and lactic acid that interfere with E. coli adhesion to epithelial cells

The vaginal colonisation point is the one that surprised early researchers. How exactly an oral capsule produces vaginal colonisation is still not fully mapped. The leading hypothesis is that the bacteria pass through the gut, are shed in faeces, and migrate the short anatomical distance to the perineum and vagina. Other species do not survive this route. GR-1 and RC-14 do.

That mechanism makes them genuinely different from a generic probiotic.

The Big Oral Trial: Beerepoot 2012

This is the trial people reach for when they argue probiotics either work or do not work for recurrent UTI. Both readings have something to them.

Beerepoot and colleagues randomised 252 postmenopausal women with at least three UTIs in the previous year to one of two arms over 12 months [4]:

• Trimethoprim-sulfamethoxazole 480 mg once daily (the standard antibiotic prophylaxis at the time)
• Oral capsules with 10⁹ CFU of L. rhamnosus GR-1 plus L. reuteri RC-14, twice daily

Going in, the women in both groups were averaging 6.8 to 7.0 UTIs in the year before the study. After 12 months of prophylaxis, the antibiotic group dropped to a mean 2.9 UTIs. The probiotic group dropped to 3.3.

The trial was designed as a non-inferiority study with a 10% margin. The probiotic group missed that margin. Statistically, the lactobacilli arm did not prove equivalent to TMP-SMX.

But the trial also measured a second outcome that mattered just as much: antibiotic resistance in E. coli isolates from the participants’ rectal flora. After three months of TMP-SMX prophylaxis, resistance to trimethoprim-sulfamethoxazole jumped from 20–40% at baseline to 80–95%. In the probiotic arm, resistance held steady. After the trial ended, the antibiotic arm’s resistance only slowly returned toward baseline over months. The probiotic arm was unaffected.

That is the realistic interpretation: GR-1 and RC-14 are slightly less effective than antibiotics over a year, but they leave your gut and bladder bacteria able to respond to antibiotics when you actually need them. For a woman dealing with recurrent UTIs over decades, that resistance trade-off is not trivial.

The Vaginal Probiotic: Lactin-V (L. crispatus CTV-05)

The strain with the strongest direct evidence for vaginal delivery is not GR-1 or RC-14. It is L. crispatus CTV-05, sold under the trade name Lactin-V.

Stapleton’s 2011 Phase 2 trial enrolled 100 premenopausal women who had just been treated for an acute UTI [5]. They were randomised to vaginal Lactin-V suppository or placebo, taken daily for 5 days then weekly for 10 weeks. After 10 weeks:

• Lactin-V group: 7 of 48 women (15%) had a culture-confirmed recurrent UTI
• Placebo group: 13 of 48 women (27%)

That is roughly a 50% relative risk reduction. Vaginal colonisation with high levels of CTV-05 was achieved in most women in the active arm, and higher colonisation was associated with lower UTI risk in a dose-response pattern. Adverse effects were limited to vaginal discharge, itching, or mild abdominal discomfort, at rates similar to placebo.

A follow-up extension showed sustained colonisation effects up to 24 weeks after the dosing period ended. Bacteria that had originally been delivered as a probiotic were still detectable as part of the woman’s resident vaginal flora.

Lactin-V is also the same product that received FDA approval for bacterial vaginosis recurrence prevention in a separate large trial. The bacterial vaginosis approval is what gives the strain real-world distribution; UTI is currently an off-label use.

Vaginal vs Oral: Murina 2024 Settled the Comparison

For years the question of whether oral or vaginal probiotics worked better for UTI prevention was answered by extrapolation. In 2024 it got a direct trial.

Murina and colleagues randomised 174 premenopausal women with recurrent UTI to four arms over 4 months: oral probiotic, vaginal probiotic, oral plus vaginal combined, or placebo [6]. UTI incidence at the end of the trial:

• Placebo: 70.4%
• Oral probiotic alone: substantially better than placebo but the worst of the three active arms
• Vaginal probiotic alone: 40.9%
• Combined oral plus vaginal: 31.8%

Two findings matter. First, both routes worked. Second, vaginal delivery beat oral, and the combination beat either route alone. The best results came from delivering Lactobacillus by both routes, presumably because the gut and the vagina are different ecosystems and probiotic effects in one do not perfectly translate to the other.

The strains used in Murina’s trial were not the same across routes. That is the unavoidable confound. Vaginal arms tend to use L. crispatus-dominant formulations because those are the strains designed for that anatomy. Oral arms tend to use GR-1 and RC-14 because those are the strains that survive the gut and translocate. So “vaginal beats oral” is partly a route effect and partly a strain effect, and pulling them apart will need a future trial.

For prevention of UTIs that follow sexual intercourse, where the vaginal microbiome is the most direct mediator, the trial-driven recommendation now leans vaginal.

The Honest Case Against

Probiotic enthusiasts tend to skip this part. The case against deserves equal weight.

The Cochrane review. Schwenger and colleagues pooled 9 RCTs covering 735 participants in 2015 [7]. The combined effect estimate was a risk ratio of 0.82, but the confidence interval crossed 1.0. In plain language: the trend favoured probiotics, but it was not statistically significant. The reviewers flagged small sample sizes, heterogeneous strains, and inconsistent outcome definitions. A decade later, the trial base is bigger but the Cochrane verdict has not been updated.

The ProSCIUTTU trial. A 2019 randomised trial tested GR-1 plus RC-14 and a separate Lactobacillus combination against placebo in 207 people with spinal cord injury and indwelling catheters or intermittent catheterisation [8]. Both probiotic arms failed. UTI rates were no different from placebo. The lesson: GR-1 and RC-14 work for community-dwelling women with intact urinary tracts. They do not appear to work for people whose UTIs are driven by catheters and biofilms.

The strain-on-the-shelf problem. The Murina, Beerepoot, and Stapleton trials all used purpose-manufactured products with known strain identity, viability counts confirmed by independent assay, and quality control matching pharmaceutical standards. Most retail probiotics are not made this way. A 2017 ConsumerLab analysis of urinary probiotics found that more than half of products tested contained CFU counts below their label claim, and several listed Lactobacillus rhamnosus without specifying a strain. A capsule labelled “L. rhamnosus” with no strain code is not the same product Beerepoot tested, even if the species name matches.

Off-target gut effects. GR-1 and RC-14 ingestion can cause mild bloating, gas, or transient diarrhoea in the first 1–2 weeks. Rates run around 10–15% in trials. People who are immunocompromised should not start any probiotic without a clinician’s input.

Comparison Table: What Has Actually Been Tested

Strain or product	Route	Evidence level	Trial dose	Best documented use	Main limitation
L. rhamnosus GR-1 + L. reuteri RC-14 (combined)	Oral	Multiple RCTs over 30 years	1–2 billion CFU/day	Postmenopausal recurrent UTI	Missed non-inferiority vs antibiotics
L. crispatus CTV-05 (Lactin-V)	Vaginal suppository	Phase 2 RCT, FDA-approved for BV	Daily x 5d, then weekly	Premenopausal recurrent UTI	Off-label for UTI; prescription-only
L. rhamnosus GG	Oral or bladder instillation	Small studies	Variable	Gut health primarily; weak UTI data	Not designed for urogenital colonisation
Generic “Lactobacillus” supplements	Oral	Untested	Variable	Unverified	Strain identity unknown
Cranberry + Lactobacillus combination	Oral	One 2025 RCT (n=80)	Variable	Recurrent UTI	Limited replication

How to Pick a Product

This is where most readers actually want practical guidance. Here is what the evidence supports.

1. Look for the strain code, not just the species. “Lactobacillus rhamnosus” is meaningless on a label. “Lactobacillus rhamnosus GR-1” tells you what is in the bottle. If the strain code is missing, treat the product as untested.

2. Match the route to the goal. For postmenopausal recurrent UTI in women with no major anatomical issues, oral GR-1 plus RC-14 has the most data. For premenopausal women with frequent post-coital UTIs, vaginal Lactin-V (where available, currently mostly via specialist clinics in the US) has the strongest direct evidence.

3. Aim for 1–2 billion CFU daily. That is what the Beerepoot trial used. Higher does not appear to do more in the published data, and lower has not been shown effective.

4. Plan for at least 12 weeks. Probiotics are not antibiotics. The mechanism is colonisation and competition, not killing, and that takes time. Trials measured outcomes at 4, 6, and 12 months. A two-week trial tells you nothing.

5. Start during or just after antibiotics, not before. The window when probiotic strains have the easiest time colonising is right after a course of antibiotics has cleared the resident flora. Counterintuitively, that is also when most clinicians forget to recommend them.

6. Combine, do not replace. Probiotics are an addition to other evidence-based UTI prevention strategies: adequate hydration, D-mannose, correctly dosed cranberry, and post-coital voiding. They are not a replacement for any of these.

Side note: the same Lactobacillus strains that protect the vagina also influence gut health, oral health, and (in some studies) skin barrier function. The body’s microbiomes talk to each other. But that is a tangent for another article.

When This Isn’t Enough

Probiotic strains for recurrent UTI are a prevention strategy. They do not treat an active infection.

If you develop burning during urination (dysuria), urinary frequency, blood in the urine (haematuria), suprapubic pain, fever, or flank pain, that is an active UTI or potentially pyelonephritis. Stop relying on the probiotic and see a doctor for culture and antibiotics.

The specific scenarios where probiotics are unlikely to be enough:

• Three or more UTIs in 12 months despite probiotic use for at least 3 months. Ask your GP about a referral to a urologist
• UTIs related to indwelling or intermittent catheters, where the evidence base does not support probiotic prevention
• Pregnancy with recurrent UTI, where different prevention strategies apply and probiotic use should be discussed with your obstetrician
• Postmenopausal women with significant atrophic vaginitis, since vaginal oestrogen often outperforms probiotics for this population and should be considered first
• Recurrent UTI plus haematuria, even if symptoms otherwise improve on probiotics, since this combination can hide structural causes that need imaging

For the broader prevention picture across delivery routes and other supplements, see the probiotics for bladder health overview.

Common Questions

What dose of GR-1 and RC-14 was used in the largest UTI trial?

The Beerepoot 2012 trial used oral capsules containing one billion CFU of GR-1 plus RC-14 taken twice daily for 12 months. That two-billion CFU daily total is the dose with the most clinical data behind it for postmenopausal women.

Are GR-1 and RC-14 better taken orally or vaginally?

GR-1 and RC-14 are formulated for oral use; they were selected partly because they survive gut transit and migrate to the vagina afterwards. The vaginal probiotic with direct UTI trial data is L. crispatus CTV-05 (Lactin-V), a different strain entirely.

Why do most probiotic supplements not list the strain code?

Strain-specific manufacturing requires verified seed cultures and quality control that adds cost. A label that says “Lactobacillus rhamnosus” can use any commercial culture stock. The strain code (GR-1, RC-14, CTV-05) is what links the product to the trials. No code, no link.

How long before probiotics for recurrent UTI start working?

Vaginal colonisation with L. crispatus is detectable within 2–4 weeks. Reduction in UTI rates appears over 10–24 weeks. Less than 8 weeks of consistent use is unlikely to show anything regardless of strain.

Can I take GR-1 and RC-14 alongside antibiotics for an active UTI?

Yes, with timing. Most clinicians recommend separating probiotic and antibiotic doses by 2–3 hours and continuing the probiotic during and after the antibiotic course to repopulate gut and vaginal flora. The probiotic does not treat the active infection. The antibiotic does.

Is L. crispatus CTV-05 more effective than GR-1 plus RC-14?

No direct comparison exists. CTV-05 (vaginal) showed roughly 50% relative reduction in Stapleton’s Phase 2 trial. GR-1 plus RC-14 (oral) fell short of antibiotic non-inferiority but reduced UTIs from a baseline of 7/year to about 3/year. The trials used different populations, different routes, and different durations, so the numbers are not directly comparable.

What to Watch For

The next 2–3 years of probiotic research will probably tell us three things the current trial base does not. Whether L. crispatus (vaginal) and GR-1 + RC-14 (oral) used in combination outperform either alone. Whether oestrogen plus vaginal probiotic outperforms either alone in postmenopausal women. And whether the strains that work for bacterial vaginosis recurrence translate to UTI prevention in the same patients. These trials are running now.

For the woman dealing with three UTIs a year today, the practical take is narrower. The probiotic strains for recurrent UTI with real evidence behind them are a small list: GR-1, RC-14, and CTV-05. The label has to say so. The trial doses were not high. The duration matters more than the dose. And the probiotic sits next to your other prevention strategies, not instead of them.

References

1. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1-13. PubMed
2. Reid G. The development of probiotics for women’s health. Can J Microbiol. 2017;63(4):269-277. PubMed
3. Anukam KC, et al. Oral use of probiotics as an adjunctive therapy to fluconazole in the treatment of yeast vaginitis. J Med Food. 2009;12(3):613-617. PubMed
4. Beerepoot MA, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012;172(9):704-712. PubMed
5. Stapleton AE, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011;52(10):1212-1217. PMC
6. Murina F, et al. Effectiveness of prophylactic oral and/or vaginal probiotic supplementation in the prevention of recurrent urinary tract infections. Clin Infect Dis. 2024;78(5):1154-1161. Oxford Academic
7. Schwenger EM, et al. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015;(12):CD008772. Cochrane
8. Toh SL, et al. Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial. Spinal Cord. 2019;57(7):550-561. Nature